Lyra Therapeutics (LYRA) EBITDA Margin (2021 - 2025)

Quarterly EBITDA Margin fell 9403732.0% to 99300.0% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 7266.08% through Dec 2025, down 117299.0% year-over-year, with the annual reading at 7266.08% for FY2025, 117299.0% down from the prior year.

Lyra Therapeutics' EBITDA Margin history spans 5 years, with the latest figure at 99300.0% for Q4 2025.

  • EBITDA Margin came in at 99300.0% for Q4 2025, down from 23936.0% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 2545.09% in Q1 2022 to a low of 129318.18% in Q4 2022.
  • The 5-year median for EBITDA Margin is 4847.61% (2021), against an average of 22160.93%.
  • Year-over-year, EBITDA Margin plummeted -12429346bps in 2022 and then surged 11896476bps in 2023.
  • Lyra Therapeutics' EBITDA Margin stood at 5024.72% in 2021, then plummeted by -2474bps to 129318.18% in 2022, then skyrocketed by 92bps to 10353.42% in 2023, then soared by 49bps to 5262.68% in 2024, then crashed by -1787bps to 99300.0% in 2025.
  • Per Business Quant, the three most recent readings for LYRA's EBITDA Margin are 99300.0% (Q4 2025), 23936.0% (Q3 2025), and 4063.93% (Q2 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Quantum Biopharma 1,384,976.65 Bn 1,384,976.64 Bn - -
2 Alterity Therapeutics 777,208.84 Bn 777,208.81 Bn - -
3 Legend Biotech 2,801.00 Bn 2,800.10 Bn 242.10 Mn -6.43%
4 Nanobiotix 2,226.01 Bn 2,225.95 Bn - -
5 Akari Therapeutics 605.66 Bn 605.66 Bn - -
6 Vertex Pharmaceuticals 110.17 Bn 102.92 Bn 2.59 Bn 38.10%
7 Regeneron Pharmaceuticals 66.86 Bn 58.11 Bn 3.31 Bn 18.35%
8 Evaxion A 65.12 Bn 65.10 Bn - -
9 Alnylam Pharmaceuticals 39.94 Bn 36.94 Bn 959.66 Mn 17.24%
10 Lyra Therapeutics - - - -99,300.00%

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 -99,300.00%
Sep 30, 2025 -23,936.00%
Jun 30, 2025 -4,063.93%
Mar 31, 2025 -4,670.49%
Dec 31, 2024 -5,262.68%
Sep 30, 2024 -6,076.41%
Jun 30, 2024 -8,053.51%
Mar 31, 2024 -4,221.80%
Dec 31, 2023 -10,353.42%
Sep 30, 2023 -2,873.35%
Jun 30, 2023 -3,413.32%
Mar 31, 2023 -3,970.00%
Dec 31, 2022 -129,318.18%
Sep 30, 2022 -4,113.09%
Jun 30, 2022 -2,736.38%
Mar 31, 2022 -2,545.09%
Dec 31, 2021 -5,024.72%
Sep 30, 2021 -78,964.29%